ARA-290 (cibinetide) is a peptide that was made from erythropoietin and is currently in phase 2 trials within the US. ARA-290 works by activating the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms. ARA-290 is used to treat neuropathic pain in patients with diabetic neuropathy, small fiber neuropathy, rheumatoid arthritis, sarcoidosis, covid induced neuropathy, and research into others is on-going and extremely promising. ARA-290 reduces nerve pain & helps repair damaged nerves, decreases systemic inflammation, accelerates wound healing, and even has been shown to help regulate blood sugar levels.
ARA-290 is prescribed for a 3 month period. The patient is started on the “high dose” for the first 6 weeks and then lowered to the “low dose” for the next 6 weeks. ARA-290 has an incredibly high safety profile, and as of yet, no study has demonstrated any side effects or toxicity; however some patients have reported an elevated BP, elevated heart rate, elevated liver enzymes, or nausea/vomiting, but these were not confirmed to be due to the medication, and could be coincidental/not drug related. Because ARA-290 is an injectable medication and not a pill, the actual injection may lead to injection site irritation or bruising, or an infection; but overall patients report it is tolerated extremely well, and results are seen in some patients as quickly as 2-3 weeks.